<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hematopoietic cell transplantation in classic Hodgkin lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hematopoietic cell transplantation in classic Hodgkin lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hematopoietic cell transplantation in classic Hodgkin lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Craig Moskowitz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvaro J Alencar, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hematopoietic cell transplantation (HCT) is an important component of treatment for relapsed and refractory (r/r) classic Hodgkin lymphoma (cHL). </p><p>This topic will review HCT for r/r cHL. The following topics are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Management of r/r cHL (see  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of patients with r/r cHL who are not eligible for HCT (see  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overviews of treatment of cHL in adults and in children (see  <a class="medical medical_review" href="/z/d/html/6246.html" rel="external">"Overview of Hodgkin lymphoma in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of the patient with cHL during and after treatment (see  <a class="medical medical_review" href="/z/d/html/4762.html" rel="external">"Monitoring of the patient with classic Hodgkin lymphoma during and after treatment"</a>)</p><p></p><p>Suggestions in this topic are consistent with guidelines of the American Society of Blood and Marrow Transplantation and the European Society for Blood and Marrow Transplantation [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H3201115729"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Definitions regarding HCT for relapsed and refractory (r/r) cHL include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> <strong>(recurrence) </strong>is the reappearance of HL at sites of prior disease and/or at new sites after achieving complete response (CR).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory (resistant) disease</strong> is the failure to achieve CR with initial therapy (primary refractory) or after salvage therapy (secondary refractory).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salvage (rescue) chemotherapy</strong> is treatment to minimize the disease burden of r/r cHL prior to HCT. Discussion of salvage therapy is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparative (conditioning) therapy </strong>is systemic treatment to ablate residual cHL and permit bone marrow engraftment by autologous or allogeneic hematopoietic cells. Conditioning regimens can be <strong>myeloablative </strong>versus<strong> nonmyeloablative</strong> (NMA) or <strong>reduced intensity conditioning </strong>(RIC). Preparative regimens (<a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">table 1</a>) are discussed below and separately. (See <a class="local">'Autologous HCT conditioning'</a> below and <a class="local">'Allogeneic HCT conditioning'</a> below and  <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous HCT</strong> utilizes the patient's own hematopoietic cells (from peripheral blood or bone marrow) to rescue hematopoiesis after preparative therapy for HCT. Indications, eligibility, and other aspects of autologous HCT for r/r cHL are discussed below. (See <a class="local">'Autologous transplantation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allogeneic HCT</strong> utilizes hematopoietic cells from another individual (eg, related donor, unrelated donor, or umbilical cord blood) for hematopoietic rescue. Indications, eligibility, and other aspects of allogeneic HCT for r/r cHL are discussed below. (See <a class="local">'Allogeneic transplantation'</a> below.)</p><p></p><p class="headingAnchor" id="H3388587034"><span class="h1">GOAL OF TRANSPLANTATION IN cHL</span><span class="headingEndMark"> — </span>The goal of HCT in relapsed or refractory (r/r) cHL is to achieve long-term disease control (ie, cure) when possible. For patients who do not achieve cure, HCT can prolong life, improve the quality of life, and/or alleviate symptoms.</p><p>Goals of HCT are influenced by the status of disease (ie, primary refractory/first relapse versus subsequent relapses), response to salvage treatment, eligibility for autologous versus allogeneic HCT, and the patient's personal goals, as described in the sections below.</p><p>Integration of HCT with other aspects of management of r/r HL is described separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H206461688"><span class="h1">AUTOLOGOUS TRANSPLANTATION</span><span class="headingEndMark"> — </span>Management of relapsed/refractory (r/r) cHL prior to autologous HCT (<a class="graphic graphic_algorithm graphicRef113183" href="/z/d/graphic/113183.html" rel="external">algorithm 1</a>) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H603930534"><span class="h2">Indications for autologous HCT</span><span class="headingEndMark"> — </span>Autologous HCT is the treatment of choice for most patients with first relapse of HL or primary refractory cHL.</p><p>Indications for autologous HCT in first relapse or primary refractory cHL (<a class="graphic graphic_algorithm graphicRef113183" href="/z/d/graphic/113183.html" rel="external">algorithm 1</a>) and integration of HCT with other aspects of management are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'Autologous HCT'</a> and  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>.)</p><p>For children with r/r cHL, our suggestions and published guidelines for autologous HCT are the same as for adults, based on a limited number of studies and extrapolation from adult data [<a href="#rid1">1,3</a>]. Other aspects of management of r/r cHL in children and adolescents are described separately. (See  <a class="medical medical_review" href="/z/d/html/6246.html" rel="external">"Overview of Hodgkin lymphoma in children and adolescents", section on 'Relapsed or refractory disease'</a>.)</p><p class="headingAnchor" id="H744844225"><span class="h2">Eligibility for autologous HCT</span><span class="headingEndMark"> — </span>There is no universal agreement regarding eligibility criteria for autologous HCT in r/r cHL. Eligibility and the risks and benefits of HCT must be discussed with the prospective patient and loved ones.</p><p>Our eligibility criteria for autologous HCT in r/r cHL include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance status</strong> – Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical fitness</strong> – Adequate cardiac, pulmonary, kidney, and liver function, and appropriate psychosocial support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – Age limits for autologous HCT vary by institution and are not absolute, but some experts suggest autologous HCT for patients ≤70 or ≤75 years of age. </p><p></p><p>Additional discussion regarding eligibility for autologous HCT is provided separately. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation", section on 'Pretransplant evaluation'</a>.)</p><p class="headingAnchor" id="H1063917377"><span class="h2">Autologous HCT conditioning</span><span class="headingEndMark"> — </span>No specific preparative regimen is considered the standard of care for autologous HCT in r/r cHL. Autologous HCT can be performed in the inpatient setting or as an outpatient (if a caregiver is available and transportation and other resource needs can be met). Prospective trials have not directly compared different preparative regimens and settings for autologous HCT.</p><p>The choice of conditioning regimen is influenced by patient comorbidities, short- and long-term toxicities, and institutional preferences, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a>.)</p><p>Our preferences for preparative regimens (<a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">table 1</a>) are:</p><p class="bulletIndent1"><span class="glyph">●</span>We (and most groups) favor <strong>BEAM</strong> (BCNU, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acceptable alternative regimens include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CBV</strong> (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, BCNU, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bu/Cy</strong> (<a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bu/Mel</strong> (<a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>)</p><p></p><p>Informative studies regarding preparative (conditioning) regimens for autologous HCT in cHL include:</p><p class="bulletIndent1"><span class="glyph">●</span>A registry study that included more than 1000 patients who underwent autologous HCT for cHL reported that, compared with BEAM conditioning, alternative regimens (eg, CBV, Bu/Cy, total body radiation) were associated with higher mortality [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two retrospective studies suggested that, compared with BEAM, other regimens may provide superior event-free survival (EFS) and/or overall survival (OS) but caused increased toxicity, but neither study included patients &gt;65 years old [<a href="#rid5">5,6</a>].</p><p></p><p class="headingAnchor" id="H2910560905"><span class="h2">Source of autologous cells</span><span class="headingEndMark"> — </span>No studies have directly compared peripheral blood versus bone marrow as the source of autologous hematopoietic cells for HCT in r/r cHL.</p><p>We and most groups favor apheresis-derived peripheral blood hematopoietic cells because of faster engraftment, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>.)</p><p class="headingAnchor" id="H1895386942"><span class="h2">Radiation of localized or bulky disease</span><span class="headingEndMark"> — </span>When relapse includes localized or bulky disease, involved-field radiation therapy (IFRT) can reduce the risk of relapse in patients who did not previously receive radiation therapy.</p><p>We suggest IFRT for patients with localized or bulky disease that was not previously radiated, but care should be taken to exclude liver and lung (to lessen the possibility of hepatic sinusoidal obstruction syndrome [veno-occlusive disease] and interstitial pneumonitis, respectively) and abdominal masses, if it would entail significant radiation exposure to the bowels. The timing of radiation therapy depends on physician/institutional preference; most centers administer IFRT after HCT, but it can also be given before HCT.</p><p>Outcomes of patients who received IFRT appear to be superior to those who did not receive IFRT, but no studies have compared the timing of consolidation IFRT (ie, before versus after HCT).</p><p>A retrospective study reported superior disease-free survival (DFS), but not OS, in 46 patients with relapsed HL who received IFRT within two months of autologous HCT, compared with 46 matched patients who underwent autologous HCT without IFRT [<a href="#rid7">7</a>]. Other retrospective studies of autologous HCT report similar outcomes [<a href="#rid7">7-12</a>].</p><p class="headingAnchor" id="H3843960157"><span class="h2">Maintenance therapy</span><span class="headingEndMark"> — </span>Maintenance therapy may benefit certain patients after autologous HCT for r/r cHL. </p><p class="headingAnchor" id="H329335741"><span class="h3">Brentuximab vedotin maintenance</span><span class="headingEndMark"> — </span>For patients who undergo autologous HCT and are at higher risk of relapse (described below), <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">brentuximab vedotin</a> (BV) maintenance therapy improves progression-free survival (PFS) when compared with observation alone. There is no proven benefit for BV maintenance for patients at lower risk of relapse or for patients who received BV as a component of initial treatment for cHL.</p><p>We suggest <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">brentuximab vedotin</a> 1.8 mg/kg (to a maximum dose of 180 mg) every three weeks beginning 30 to 45 days after HCT for up to 16 cycles (10 cycles for those who received BV as salvage therapy) for patients with at least one but preferably two of the following high-risk features:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary refractory cHL or relapse &lt;12 months after initial therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less than complete response (CR) to most recent salvage therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>B symptoms at relapse</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapse with extranodal disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two or more salvage therapies</p><p></p><p>We do not administer BV maintenance to patients who do not meet these high-risk criteria, were intolerant of BV, or if cHL progressed while receiving BV. For patients who received BV as a component of initial therapy, we limit BV maintenance to those who meet high-risk criteria and relapsed &gt;12 months after an adequate initial response to BV. Peripheral neuropathy is seen in more than half of patients treated with maintenance BV, but it improves or resolves in most after discontinuation; motor neuropathy and neutropenia are seen in one-quarter to one-third of patients. </p><p>In the multicenter AETHERA trial, 329 BV-naïve patients who underwent autologous HCT with the high-risk features described above were randomly assigned to maintenance therapy with BV versus placebo [<a href="#rid13">13</a>]. Compared with placebo, BV was associated with superior five-year PFS (59 versus 41 percent; HR 0.52; 95% CI 0.38-0.72) [<a href="#rid14">14</a>]. OS did not differ between the two arms of the trial, but the analysis was limited by the large number of patients on the placebo arm who crossed over to BV treatment after progression. BV was associated with more peripheral sensory neuropathy (56 versus 16 percent, respectively), peripheral motor neuropathy (23 versus 2 percent), and neutropenia (35 versus 12 percent). With five-year follow-up, peripheral neuropathy improved in 90 percent and completely resolved in 73 percent.</p><p class="headingAnchor" id="H259806623"><span class="h3">PD-1 blockade maintenance</span><span class="headingEndMark"> — </span>Maintenance therapy with a PD-1 inhibitor may provide clinical benefit following autologous HCT for r/r cHL. Use of PD-1 inhibitors for other aspects of treatment of r/r cHL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'PD-1 blockade'</a>.)</p><p>A multicenter study administered <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> 200 mg intravenously every three weeks for up to eight cycles beginning within 21 days post autologous HCT hospital discharge [<a href="#rid15">15</a>]. At 18 months, the PFS was 82 percent and OS was 100 percent among 28 evaluable patients. Toxicity was manageable, with 30 percent experiencing ≥1 grade 3 adverse event (AE) and 40 percent ≥1 grade 2 immune-related AE. While promising, maintenance therapy with PD-1 blockade must be validated in other studies before suggesting its use.</p><p class="headingAnchor" id="H4162705312"><span class="h2">Tandem autologous HCT</span><span class="headingEndMark"> — </span>No randomized studies have directly compared tandem (ie, sequential) autologous HCT with single autologous HCT for r/r cHL. However, uncontrolled prospective studies have demonstrated no clear benefits for tandem transplantation, even for patients with adverse prognostic features [<a href="#rid16">16-19</a>].</p><p>We do not offer tandem autologous HCT for r/r cHL outside of the setting of a clinical trial.</p><p class="headingAnchor" id="H3124093344"><span class="h2">Prognostic factors for autologous HCT in cHL</span><span class="headingEndMark"> — </span>No studies have prospectively evaluated prognostic factors for autologous HCT in r/r cHL. Retrospective studies have reported that worse outcomes were associated with incomplete positron emission tomography (PET) response to salvage chemotherapy, presence of B symptoms, short duration of remission (ie, less than one year), extranodal disease, more than one prior chemotherapy regimen, and poor performance status [<a href="#rid20">20-41</a>].</p><p>A prognostic model to predict PFS after HCT was developed based on the outcomes of 337 patients with r/r cHL who underwent autologous HCT, and was validated in a separate cohort of 391 patients [<a href="#rid26">26</a>]. A multivariate model identified the following four major risk factors at the time of HCT with each factor assigned a relative weight:</p><p class="bulletIndent1"><span class="glyph">●</span>Poor performance status (Karnofsky performance score &lt;90) (<a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">table 3</a>) – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy-resistant disease – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;3 prior chemotherapy regimens – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Extranodal disease – 2 points</p><p></p><p>Three risk groups were identified based on the sum of the total score: low risk (score 0), intermediate risk (score 1 to 3), and high risk (score 4 to 6); the four-year PFS rates for these groups were 71, 60, and 42 percent, respectively.</p><p class="headingAnchor" id="H427929288"><span class="h1">ALLOGENEIC TRANSPLANTATION</span><span class="headingEndMark"> — </span>Management of multiply relapsed/refractory (r/r) cHL prior to allogeneic HCT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H2841566633"><span class="h2">Indications for allogeneic HCT</span><span class="headingEndMark"> — </span>We generally limit allogeneic HCT to medically-eligible patients who were previously treated with <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">brentuximab vedotin</a> (BV) and autologous HCT and who had only a partial response or progressive disease after immune checkpoint inhibition (ICI). We generally do not proceed with allogeneic HCT for patients who had a complete response (CR) with ICI. </p><p>Allogeneic HCT in patients who were previously treated with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> may be associated with an increased risk for acute graft-versus-host disease (GVHD), hyperacute GVHD, chronic GVHD, hepatic sinusoidal obstructive syndrome (SOS, also called veno-occlusive disease) after reduced intensity conditioning, and glucocorticoid-requiring febrile syndrome (with an identified infectious disease).</p><p>In settings where ICI is not available, allogeneic HCT may be considered for patients with r/r cHL following autologous HCT.</p><p class="headingAnchor" id="H2799641149"><span class="h2">Eligibility for allogeneic HCT</span><span class="headingEndMark"> — </span>Age, medical fitness, and risk category inform eligibility for allogeneic HCT in r/r cHL, but criteria vary between institutions. Our approach follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk category</strong> – Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.hctci.org%2F&amp;token=ynHAjPAj9CyAh2PR1lP9qZhGSdEf0yCBdRFTCKXhmz4%3D&amp;TOPIC_ID=4760" target="_blank">www.hctci.org</a>) is a useful tool for assessing risk prior to allogeneic HCT [<a href="#rid42">42</a>]. There is no HCT-CI score that we consider an absolute exclusion to allogeneic HCT, but outcomes are less favorable for patients with HCT-CI score ≥5, and we discuss the higher risk and lower expectations of HCT in this setting with the patient and loved ones. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical fitness</strong> – Medical fitness for allogeneic HCT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – Most institutions restrict reduced intensity conditioning (RIC)/nonmyeloablative (NMA) HCT to patients ≤70 years old. For institutions that offer myeloablative HCT in this setting, allogeneic HCT is typically limited to patients ≤60 years old. </p><p></p><p class="headingAnchor" id="H811535890"><span class="h2">Allogeneic donor source</span><span class="headingEndMark"> — </span>We favor related-donor allogeneic hematopoietic cells for allogeneic HCT for r/r cHL, when available. Details of donor selection for allogeneic HCT are provided separately. (See  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p>A systematic review concluded that all donor sources, including related, unrelated, and haploidentical donors, and umbilical cord blood were reasonable options for allogeneic HCT in patients with cHL [<a href="#rid43">43</a>]. Other studies have reported similar conclusions [<a href="#rid44">44,45</a>].</p><p class="headingAnchor" id="H902876712"><span class="h2">Bridging therapy</span><span class="headingEndMark"> — </span>There should be adequate disease control prior to transplant. C-MOPP (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9815" href="/z/d/drug information/9815.html" rel="external">procarbazine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) or another alkylator-based chemotherapy can be used as bridging therapy to achieve disease control. </p><p class="headingAnchor" id="H1996373692"><span class="h2">Allogeneic HCT conditioning</span><span class="headingEndMark"> — </span>RIC or NMA preparative regimens are preferred for allogeneic HCT in r/r cHL. Some institutions offer myeloablative allogeneic HCT in this setting.</p><p>RIC and NMA preparative regimens (<a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">table 1</a>) provide graft-versus-lymphoma effects with less toxicity than myeloablative regimens. Selection of RIC versus NMA conditioning is based on institutional preferences, and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation", section on 'NMA and RIC regimens'</a>.)</p><p>Our preferred RIC regimen is <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> and <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> [<a href="#rid44">44,46-48</a>]; some centers add <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> to this regimen [<a href="#rid49">49,50</a>].</p><p>RIC/NMA conditioning offers a survival advantage when compared with myeloablative approaches for allogeneic HCT in r/r cHL. As an example, a retrospective analysis of 168 patients reported that, compared with myeloablative HCT, RIC was associated with improved overall survival (OS; HR 2.1, 95% CI 1.3-3.3) and lower nonrelapse mortality (NRM; HR 2.9, 95% CI 1.6-5.0), despite an increased risk of relapse or progression [<a href="#rid51">51</a>]. Another retrospective comparison of 312 patients reported no significant difference between myeloablative and RIC allogeneic HCT with regard to relapse rate, NRM, event-free survival (EFS), or OS [<a href="#rid52">52</a>].</p><p>Informative studies regarding RIC/NMA conditioning allogenic HCT for r/r cHL include:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective Spanish study of 78 patients reported one-year and four-year PFS rates were 48 and 24 percent, respectively, and the one-year and four-year OS rates were 71 and 43 percent, respectively [<a href="#rid53">53</a>]. NRM at one year was 15 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retrospective analysis of 191 French patients who underwent RIC regimens reported three-year rates of OS, PFS, relapse, and NRM were 63, 39, 46, and 16 percent, respectively [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1">A retrospective study of 143 patients reported PFS and OS of 30 and 50 percent at one year, and 20 and 37 percent at two years [<a href="#rid55">55</a>]. Rates of treatment-related mortality at 100 days and two years were 15 and 33 percent, respectively.</p><p></p><p class="headingAnchor" id="H3812960934"><span class="h2">Post-HCT management</span><span class="headingEndMark"> — </span>Following allogeneic HCT, we offer radiation therapy to localized or bulky disease that was not previously radiated, and we offer maintenance BV therapy to BV-naïve patients, as described above. (See <a class="local">'Radiation of localized or bulky disease'</a> above and <a class="local">'Maintenance therapy'</a> above.)</p><p>Management of GVHD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">"Treatment of acute graft-versus-host disease"</a>.)</p><p>Surveillance after allogeneic HCT is discussed below. (See <a class="local">'Post-HCT surveillance'</a> below.)</p><p class="headingAnchor" id="H434572900"><span class="h2">Prognostic factors for allogeneic HCT</span><span class="headingEndMark"> — </span>Only limited data regarding prognostic factors after allogeneic HCT for r/r cHL are available. A systematic review and meta-analysis of 42 studies reported that achieving remission prior to allogeneic HCT was associated with improved OS at two years and improved relapse-free survival at one year [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1590432491"><span class="h1">POST-HCT SURVEILLANCE</span><span class="headingEndMark"> — </span>Patients are seen at periodic intervals to monitor disease status, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4762.html" rel="external">"Monitoring of the patient with classic Hodgkin lymphoma during and after treatment"</a>.)</p><p>Transplant recipients are at risk of developing therapy-related complications for years after treatment, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4764.html" rel="external">"Second malignancies after treatment of classic Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor"</a> and  <a class="medical medical_review" href="/z/d/html/14232.html" rel="external">"Approach to the adult survivor of classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H258719426"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15854.html" rel="external">"Patient education: Autologous bone marrow transplant (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/117867.html" rel="external">"Patient education: Allogeneic bone marrow transplant (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/683.html" rel="external">"Patient education: Hodgkin lymphoma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H278308787"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Autologous hematopoietic cell transplantation (HCT) can cure more than half of patients with classic Hodgkin lymphoma (cHL) that relapsed after initial complete response (CR) or failed to achieve initial CR (primary refractory cHL). (See <a class="local">'Definitions'</a> above and <a class="local">'Goal of transplantation in cHL'</a> above.)</p><p></p><p class="bulletIndent1">Allogeneic HCT can cure a subset of patients with subsequent relapses of cHL, and extend survival, improve the quality of life, and/or alleviate symptoms for others.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indications for HCT and integration of HCT with other aspects of management of relapsed/refractory cHL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eligibility for HCT depends on the choice of autologous versus allogeneic HCT, medical fitness, age, and response to salvage therapy, as described above. (See <a class="local">'Eligibility for autologous HCT'</a> above and <a class="local">'Eligibility for allogeneic HCT'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <strong>autologous HCT</strong>, we offer BEAM (BCNU, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>) conditioning (<a class="graphic graphic_table graphicRef90901" href="/z/d/graphic/90901.html" rel="external">table 1</a>) and peripheral blood as the source of hematopoietic cells, as discussed above. (See <a class="local">'Autologous transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For previously unirradiated localized or bulky disease we suggest involved-field radiation therapy (IFRT) after HCT rather than observation alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This suggestion is based on limited evidence that radiation after autologous HCT is associated with improved disease control but has no impact on overall survival. (See <a class="local">'Radiation of localized or bulky disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For brentuximab-naïve patients at high risk of relapse or progression (ie, primary refractory disease, relapse &lt;12 months after initial therapy, or relapsed with extranodal disease) we suggest maintenance therapy with <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">brentuximab vedotin</a> (BV) rather than observation alone until progression (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). This suggestion is based on more favorable progression-free survival with BV maintenance coupled with acceptable toxicity. For patients who received BV as a component of initial therapy, we limit BV maintenance to those who meet high-risk criteria and relapsed &gt;12 months after an adequate initial response to BV. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We limit <strong>allogeneic HCT </strong>to medically-eligible patients who were previously treated with BV and autologous HCT and who had only a partial response or progressive disease after immune checkpoint inhibition (ICI); we generally do not proceed with allogeneic HCT for patients who had a CR with ICI. (See <a class="local">'Allogeneic transplantation'</a> above.)</p><p></p><p class="headingAnchor" id="H1153800897"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges George P Canellos, MD, Peter M Mauch, MD, and Ginna G Laport, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Perales MA, Ceberio I, Armand P, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21:971.</a></li><li><a class="nounderline abstract_t">Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50:1037.</a></li><li><a class="nounderline abstract_t">Harker-Murray PD, Drachtman RA, Hodgson DC, et al. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2014; 61:579.</a></li><li><a class="nounderline abstract_t">Chen YB, Lane AA, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21:1046.</a></li><li><a class="nounderline abstract_t">Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013; 19:410.</a></li><li><a class="nounderline abstract_t">Bains T, Chen AI, Lemieux A, et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014; 55:583.</a></li><li><a class="nounderline abstract_t">Kahn S, Flowers C, Xu Z, Esiashvili N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 2011; 81:175.</a></li><li><a class="nounderline abstract_t">Garfin PM, Link MP, Donaldson SS, et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. Biol Blood Marrow Transplant 2015; 21:326.</a></li><li><a class="nounderline abstract_t">Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119:1665.</a></li><li><a class="nounderline abstract_t">Evens AM, Altman JK, Mittal BB, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol 2007; 18:679.</a></li><li><a class="nounderline abstract_t">Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002; 29:303.</a></li><li><a class="nounderline abstract_t">Wendland MM, Asch JD, Pulsipher MA, et al. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol 2006; 29:189.</a></li><li><a class="nounderline abstract_t">Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385:1853.</a></li><li><a class="nounderline abstract_t">Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018; 132:2639.</a></li><li><a class="nounderline abstract_t">Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 2019; 134:22.</a></li><li><a class="nounderline abstract_t">Morschhauser F, Brice P, Fermé C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26:5980.</a></li><li><a class="nounderline abstract_t">Sibon D, Morschhauser F, Resche-Rigon M, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica 2016; 101:474.</a></li><li><a class="nounderline abstract_t">Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007; 13:594.</a></li><li><a class="nounderline abstract_t">Smith EP, Hongli L, Friedberg JW, et al. SWOG S0410/BMT CTN 0703: A phase II trial of tandem autologous stem cell transplantation (AHCT) for patients with primary progressive or recurrent Hodgkin lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987). Blood 2014; :abstract 676.</a></li><li><a class="nounderline abstract_t">Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25:2000.</a></li><li><a class="nounderline abstract_t">Popat U, Hosing C, Saliba RM, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33:1015.</a></li><li><a class="nounderline abstract_t">Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106:1473.</a></li><li><a class="nounderline abstract_t">Stiff PJ, Unger JM, Forman SJ, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9:529.</a></li><li><a class="nounderline abstract_t">Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97:2748.</a></li><li><a class="nounderline abstract_t">Constans M, Sureda A, Terol MJ, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 2003; 14:745.</a></li><li><a class="nounderline abstract_t">Hahn T, McCarthy PL, Carreras J, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant 2013; 19:1740.</a></li><li><a class="nounderline abstract_t">Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625.</a></li><li><a class="nounderline abstract_t">Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12:1065.</a></li><li><a class="nounderline abstract_t">Greaves P, Wilson A, Matthews J, et al. Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. Br J Haematol 2012; 157:201.</a></li><li><a class="nounderline abstract_t">Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616.</a></li><li><a class="nounderline abstract_t">Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001; 113:161.</a></li><li><a class="nounderline abstract_t">Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32:279.</a></li><li><a class="nounderline abstract_t">Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16:116.</a></li><li><a class="nounderline abstract_t">Wadehra N, Farag S, Bolwell B, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:1343.</a></li><li><a class="nounderline abstract_t">Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 2007; 39:41.</a></li><li><a class="nounderline abstract_t">Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486.</a></li><li><a class="nounderline abstract_t">Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13:1370.</a></li><li><a class="nounderline abstract_t">Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20:221.</a></li><li><a class="nounderline abstract_t">Martínez C, Salamero O, Arenillas L, et al. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution. Leuk Lymphoma 2007; 48:1968.</a></li><li><a class="nounderline abstract_t">Qazilbash MH, Devetten MP, Abraham J, et al. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Acta Haematol 2003; 109:119.</a></li><li><a class="nounderline abstract_t">Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 2011; 153:358.</a></li><li><a class="nounderline abstract_t">Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013; 121:2854.</a></li><li><a class="nounderline abstract_t">Messer M, Steinzen A, Vervölgyi E, et al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review. Leuk Lymphoma 2014; 55:296.</a></li><li><a class="nounderline abstract_t">Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93:257.</a></li><li><a class="nounderline abstract_t">Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94:230.</a></li><li><a class="nounderline abstract_t">Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35:943.</a></li><li><a class="nounderline abstract_t">Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12:172.</a></li><li><a class="nounderline abstract_t">Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011; 90:803.</a></li><li><a class="nounderline abstract_t">Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365:1934.</a></li><li><a class="nounderline abstract_t">Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011; 29:971.</a></li><li><a class="nounderline abstract_t">Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:455.</a></li><li><a class="nounderline abstract_t">Genadieva-Stavrik S, Boumendil A, Dreger P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol 2016; 27:2251.</a></li><li><a class="nounderline abstract_t">Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97:310.</a></li><li><a class="nounderline abstract_t">Marcais A, Porcher R, Robin M, et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2013; 98:1467.</a></li><li><a class="nounderline abstract_t">Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15:109.</a></li><li><a class="nounderline abstract_t">Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant 2016; 51:521.</a></li></ol></div><div id="topicVersionRevision">Topic 4760 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773017" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25798672" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504790" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25687795" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128322" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23697844" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20732769" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25445024" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184409" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307757" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896427" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601441" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25796459" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266774" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30952672" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018090" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721893" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448919" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : SWOG S0410/BMT CTN 0703: A phase II trial of tandem autologous stem cell transplantation (AHCT) for patients with primary progressive or recurrent Hodgkin lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420510" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15048145" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870180" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12931122" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767087" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702529" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24096096" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15737986" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084370" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22224653" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157476" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328296" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858199" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598948" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162217" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17115062" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003382" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196362" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773173" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917965" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714820" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410449" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355537" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : How I assess comorbidities before hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656201" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18223284" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066328" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806128" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443515" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21210120" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936420" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282545" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086796" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28007754" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21993674" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539540" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135949" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26726948" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
